[Clinical study of S-6437 in pediatrics (author's transl)].
Clinical study of sustained release cephalexin (granules, 200 mg/g, S-6437) was conducted in pediatric patients as follows: 1. For infants under 20 kg of body weight, 25 approximately 50 mg/kg/day of this preparation (or 50 approximately 100 mg/kg/day for severe diseases) were given in two divided doses, and for infants over 20 kg, 1 g (or 2 g for severe diseases) were administered at two divided doses. 2. Patients treated with this preparation were 27 cases with scarlet fever, 3 with acute pharyngitis, 2 with acute tonsillitis, 1 with acute laryngitis, 1 with acute cystitis and 1 with acute enteritis. 3. Out of the 35 patients, 11 showed "very good" response to this preparation, 18 "good", 3 "fair", 1 "poor", and 2 "unknown" indicating 87.9% of effectiveness. 4. Side effects of cheilitis in one patient and vomiting in 1 were observed, and other 2 patients had difficulty in taking this preparation. No other side effects were found.
D000208:Acute Disease; D000367:Age Factors; D002506:Cephalexin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003556:Cystitis / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004751:Enteritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012541:Scarlet Fever / Q000188:drug therapy
D003692:Delayed-Action Preparations; D002506:Cephalexin